BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karpel-Massler G, Kast RE, Siegelin MD, Dwucet A, Schneider E, Westhoff MA, Wirtz CR, Chen XY, Halatsch ME, Bolm C. Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification. Neurochem Res 2017;42:3382-9. [PMID: 28852934 DOI: 10.1007/s11064-017-2378-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Kast RE. Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment. Med Sci (Basel) 2018;6:E84. [PMID: 30274295 DOI: 10.3390/medsci6040084] [Reference Citation Analysis]
2 Georgikou C, Buglioni L, Bremerich M, Roubicek N, Yin L, Gross W, Sticht C, Bolm C, Herr I. Novel Broccoli Sulforaphane-Based Analogues Inhibit the Progression of Pancreatic Cancer without Side Effects. Biomolecules 2020;10:E769. [PMID: 32429039 DOI: 10.3390/biom10050769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Yu H, Li Z, Bolm C. Three-Dimensional Heterocycles by Iron-Catalyzed Ring-Closing Sulfoxide Imidation. Angew Chem 2018;130:12229-32. [DOI: 10.1002/ange.201804284] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
4 Kast RE. Dapsone as treatment adjunct in ARDS. Exp Lung Res 2020;46:157-61. [PMID: 32286085 DOI: 10.1080/01902148.2020.1753266] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
5 Kast RE. Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation. Med Sci (Basel) 2021;9:12. [PMID: 33669324 DOI: 10.3390/medsci9010012] [Reference Citation Analysis]
6 Wen J, Cheng H, Raabe G, Bolm C. Rhodium-Catalyzed [4 + 3] Annulations of Sulfoximines with α,β-Unsaturated Ketones Leading to 1,2-Benzothiazepine 1-Oxides. Org Lett 2017;19:6020-3. [DOI: 10.1021/acs.orglett.7b03106] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis]
7 Lyne SB, Yamini B. An Alternative Pipeline for Glioblastoma Therapeutics: A Systematic Review of Drug Repurposing in Glioblastoma. Cancers (Basel) 2021;13:1953. [PMID: 33919596 DOI: 10.3390/cancers13081953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Basheer AS, Abas F, Othman I, Naidu R. Role of Inflammatory Mediators, Macrophages, and Neutrophils in Glioma Maintenance and Progression: Mechanistic Understanding and Potential Therapeutic Applications. Cancers (Basel) 2021;13:4226. [PMID: 34439380 DOI: 10.3390/cancers13164226] [Reference Citation Analysis]
9 Halatsch ME, Kast RE, Dwucet A, Hlavac M, Heiland T, Westhoff MA, Debatin KM, Wirtz CR, Siegelin MD, Karpel-Massler G. Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. Br J Pharmacol 2019;176:3681-94. [PMID: 31222722 DOI: 10.1111/bph.14773] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
10 Li Z, Frings M, Yu H, Bolm C. Organocatalytic Synthesis of Sulfoximidoyl-Containing Carbamates from Sulfoximines and Morita–Baylis–Hillman Carbonates. Org Lett 2019;21:3119-22. [DOI: 10.1021/acs.orglett.9b00772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Li Z, Frings M, Yu H, Raabe G, Bolm C. Organocatalytic Asymmetric Allylic Alkylations of Sulfoximines. Org Lett 2018;20:7367-70. [DOI: 10.1021/acs.orglett.8b03003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
12 Horn T, Bettray W, Noll U, Krauskopf F, Huang MR, Bolm C, Slusarenko AJ, Gruhlke MCH. The Sulfilimine Analogue of Allicin, S-Allyl-S-(S-allyl)-N-Cyanosulfilimine, Is Antimicrobial and Reacts with Glutathione. Antioxidants (Basel) 2020;9:E1086. [PMID: 33158268 DOI: 10.3390/antiox9111086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
13 Yu H, Li Z, Bolm C. Iron(II)-Catalyzed Direct Synthesis of NH Sulfoximines from Sulfoxides. Angew Chem Int Ed 2018;57:324-7. [DOI: 10.1002/anie.201710498] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 10.5] [Reference Citation Analysis]
14 Yu H, Li Z, Bolm C. Three-Dimensional Heterocycles by Iron-Catalyzed Ring-Closing Sulfoxide Imidation. Angew Chem Int Ed 2018;57:12053-6. [DOI: 10.1002/anie.201804284] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
15 Wang C, Li Q, Li T. Dioscin alleviates lipopolysaccharide-induced acute lung injury through suppression of TLR4 signaling pathways. Exp Lung Res 2020;46:11-22. [PMID: 31931639 DOI: 10.1080/01902148.2020.1711830] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Brosge F, Kochs JF, Bregu M, Truong KN, Rissanen K, Bolm C. 5-Carbonyl-1,3-oxazine-2,4-diones from N-Cyanosulfoximines and Meldrum's Acid Derivatives. Org Lett 2020;22:6667-70. [PMID: 32806203 DOI: 10.1021/acs.orglett.0c02504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yu H, Li Z, Bolm C. Iron(II)-Catalyzed Direct Synthesis of NH Sulfoximines from Sulfoxides. Angew Chem 2018;130:330-3. [DOI: 10.1002/ange.201710498] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
18 Brosge F, Lorenz T, Helten H, Bolm C. BN- and BO-Doped Inorganic-Organic Hybrid Polymers with Sulfoximine Core Units. Chemistry 2019;25:12708-11. [PMID: 31433083 DOI: 10.1002/chem.201903289] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]